



PATENT


ATTORNEY DOCKET NO. 50211/006002

#9  
ID #attach.  
5.8.3Certificate of Mailing: Date of Deposit: April 30, 2003

I hereby certify under 37 C.F.R. § 1.8(a) that this correspondence is being deposited with the United States Postal Service as **first class mail** with sufficient postage on the date indicated above and is addressed to the Commissioner for Patents, Washington, D.C. 20231.

Susan M. Cannon

Printed name of person mailing correspondence

  
Signature of person mailing correspondence

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	Judes Poirier	Art Unit:	1648
Serial No.:	09/500,162	Examiner:	Parkin, Jeffrey S.
Filed:	February 8, 2000	Customer No.:	21559
Title:	PHARMACOGENETIC METHODS FOR USE IN THE TREATMENT OF NERVOUS SYSTEM DISEASE		

Commissioner for Patents  
Washington, D.C. 20231

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Applicant submits the references listed on the enclosed Form PTO-1449, copies of which are enclosed.

Submission of this statement is not a representation that a search has been made, nor is the inclusion of information in this statement an admission that the information is material to patentability.


This statement is being filed after a first Office action on the merits, but before the mailing of a final Office action or a Notice of Allowance. A check for \$180.00 in payment of the late submission fee of 37 C.F.R. § 1.17(p) is enclosed.

If there are any other charges or any credits, please apply them to Deposit Account

No. 03-2095.

Respectfully submitted,

Date: 30 April 2003

  
Kristina Bieker-Brady, Ph.D.  
Reg. No. 39,109

KAREN L. ELBING  
REG NO 35,238  
FOR

Clark & Elbing LLP  
101 Federal Street  
Boston, MA 02110  
Telephone: 617-428-0200  
Facsimile: 617-428-7045  
50211.006002 Supplemental IDS.doc



21559

PATENT TRADEMARK OFFICE